Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Hansa Biopharma ABEli Lilly
Last price
kr 46.64$1,427.28
Currency
SEK
USD
kr 4.6B$1.3T
-46.65
-kr 7.71$30.81
-0.39
0$6.69
00.48%
Sector
HealthHealth
Employees
13150,000
Ticker
Skr HNSA$LLY
Primary listing
XSTONYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in SkrHNSA or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.